Moderna(US:MRNA) Benzinga·2025-12-15 18:01Core Insights - Deep-pocketed investors are showing a bullish sentiment towards Moderna, indicating potential significant developments ahead [1] - The options activity for Moderna is unusually high, with 60% of investors leaning bullish and 30% bearish [2] Options Activity Summary - A total of 10 extraordinary options activities were recorded for Moderna, with 4 puts totaling $442,603 and 6 calls amounting to $345,665 [2] - The average open interest for Moderna options is 1508.67, with a total volume of 3,911.00, indicating strong trading interest [4] Price Movement Expectations - Investors have been targeting a price range for Moderna between $22.0 and $39.0 over the last three months [3] - Significant options trades include a bearish put option with a strike price of $27.00 and a total trade price of $347.9K, alongside various call options with differing sentiments [8] Company Overview - Moderna is a commercial-stage biotech founded in 2010, known for its mRNA technology validated by its COVID-19 vaccine [9] - The company has 35 mRNA development candidates in clinical studies across various therapeutic areas as of August 2025 [9] Analyst Ratings - Analysts have set an average price target of $32.8 for Moderna, with varying ratings from different firms, including a target of $25 from RBC Capital and $63 from Piper Sandler [11][12]